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Abstract
Introduction: Liver × receptors (LXRs) are members of the nuclear receptor family of ligand-dependent
transcription factors and have established functions as regulators of cholesterol, glucose, and fatty acid metabolism
and inflammatory responses. Published reports of anti-proliferative effects of synthetic LXR ligands on breast,
prostate, ovarian, lung, skin, and colorectal cancer cells suggest that LXRs are potential targets in cancer prevention
and treatment.
Methods: To further determine the effects of LXR ligands and identify their potential mechanisms of action in
breast cancer cells, we carried out microarray analysis of gene expression in four breast cancer cell lines following
treatments with the synthetic LXR ligand GW3965. Differentially expressed genes were further subjected to gene
ontology and pathway analyses, and their expression profiles and associations with disease parameters and
outcomes were examined in clinical samples. Response of E2F target genes were validated by real-time PCR, and
the posited role of E2F2 in breast cancer cell proliferation was tested by RNA interference experiments.
Results: We observed cell line-specific transcriptional responses as well as a set of common responsive genes. In
the common responsive gene set, upregulated genes tend to function in the known metabolic effects of LXR
ligands and LXRs whereas the downregulated genes mostly include those which function in cell cycle regulation,
DNA replication, and other cell proliferation-related processes. Transcription factor binding site analysis of the
downregulated genes revealed an enrichment of E2F binding site sequence motifs. Correspondingly, E2F2
transcript levels are downregulated following LXR ligand treatment. Knockdown of E2F2 expression, similar to LXR
ligand treatment, resulted in a significant disruption of estrogen receptor positive breast cancer cell proliferation.
Ligand treatment also decreased E2F2 binding to cis-regulatory regions of target genes. Hierarchical clustering of
breast cancer patients based on the expression profiles of the commonly downregulated LXR ligand-responsive
genes showed a strong association of these genes with patient survival.
Conclusions: Taken together, these results indicate that LXR ligands target gene networks, including those
regulated by E2F family members, are critical for tumor biology and disease progression and merit further
consideration as potential agents in the prevention and treatment of breast cancers.
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Introduction
Advances in breast cancer therapy are facilitated by
molecular characterizations of tumors and tumor sub-
types. For example, breast tumors that express estrogen
receptor (ER-positive, ER+) and progesterone receptor
(PR-positive, PR+) and are dependent on the female sex
hormone estrogen for growth and proliferation are trea-
ted by drugs that target ER either directly (tamoxifen,
raloxifene, fulvestrant) or indirectly (letrozole, anastro-
zole, exemestane) by disrupting estrogen production
[1,2]. Tumors that overexpress human epidermal growth
factor receptor 2 (HER2/ErbB-2/neu+) on cell surfaces
are targeted by monoclonal antibodies (trastuzumab) or
tyrosine kinase inhibitors (lapatinib), which block recep-
tor activation and tumor cell proliferation [3]. Some
tumors, however, are refractory to these targeted thera-
pies or develop resistance over time. Blocking estrogen
production and functions also imparts menopausal
symptoms and increases corresponding health risks in
premenopausal women. Moreover, a significant number
of patients have triple negative (ER-, PR-, and HER2-)
breast cancers and require alternative targeted chemo-
preventive and therapeutic strategies [4]. Improvements
of current breast cancer therapeutics and development
of new ones necessitate the discovery and characteriza-
tion of novel target mechanisms and targeting agents.
Both ER and PR belong to the nuclear receptor (NR)
superfamily of ligand-dependent transcription factors,
which function in normal development and physiology
and in a number of human diseases [5]. NRs are highly
druggable targets of synthetic and natural ligands, and
accumulating insights on NR structures and functions
and advances in medicinal chemistry have provided
receptor-selective, full, partial and inverse agonists and
antagonists, as well as compounds that activate only a
subset of the NR functions or in a tissue-specific man-
ner. Discovery and characterization of other NRs that
may also play important roles in breast cancer biology
are, therefore, likely to yield other promising target
mechanisms and agents.
Liver × receptors (LXRs) are NRs that are activated by
oxysterols, synthetic ligands, and dietary phytosterols and
have been well characterized as regulators of cholesterol,
glucose, and fatty acid metabolism and inflammatory
responses [6-12]. At the molecular level, two receptor
subtypes, LXRa and LXRb, function in heterodimers
with 9-cis retinoic acid receptors (RXRs), and their activ-
ities as transcriptional regulators are modulated by ligand
binding and post-translational modifications mediated by
cell signaling pathways [13]. A number of LXR ligands
have been developed for the treatment of atherosclerosis,
diabetes, Alzheimer’s disease, and inflammation. Pub-
lished reports of anti-proliferative effects of LXR ligands
on breast, prostate, ovarian, lung, skin, and colorectal
cancer cells suggest that LXRs are potential targets in
cancer prevention and treatment [14-17]. Observations
of increased proliferation markers in colon tissues and
pre-neoplastic lesions in the gallbladder of LXRb knock-
out animals further suggest a role for LXRs and their
ligands in cancer initiation and progression [18,19]. We
have previously shown that synthetic LXR ligands can
block the proliferation of both ER+ and ER- breast cancer
cells through downregulation of some cell cycle and
growth-associated genes [20]. To additionally determine
the effects of LXR ligands on breast cancer cells and to
identify their potential mechanisms of action, we carried
out microarray analysis of gene expression following
treatment with the synthetic LXR ligand GW3965 in
multiple breast cancer cell lines. Here, we report our
findings regarding the effects of LXR activation on breast
cancer transcriptomes, the potential role of E2F2 in med-
iating the anti-proliferative effects in ER+ breast cancer
cells, and association of ligand-responsive gene networks
with disease outcomes in breast cancer patients.
Materials and methods
Cell culture and treatment
MCF-7 ER+ breast cancer cells were cultured in DMEM
(Invitrogen, Carlsbad, CA, USA) supplemented with 10%
FBS (Saveen Werner, Limhamn, Sweden or Hyclone,
Logan, UT, USA). ER+ T-47D cells were cultured in
DMEM:F12 (Invitrogen) supplemented with 5% FBS.
ER- SK-BR-3 and MDA-MB-231 cells were grown in
Roswell Park Memorial Institute (RPMI) 1640 medium
(Invitrogen) supplemented with 10% FBS. For microar-
ray analysis, cells were treated with 10 μM of the syn-
thetic LXR ligand GW3965 for 48 hours before harvest
and RNA isolation with EZNA Total RNA Kit I (Omega
Bio-Tek, Norcross, GA, USA) according to the manufac-
turer’s protocol. Current institutional and governmental
safety guidelines were followed in the performance of
these experiments, and no additional ethical approval
was required from institutional review boards.
Microarray and data analysis
We amplified 250 ng of RNA, which was converted to
cRNA using the Illumina TotalPrep-96 RNA Amplifica-
tion kit (Ambion, Carlsbad, CA, USA): 750 ng of cRNA
was used for hybridization onto the Illumina Whole-
Genome Gene Expression Direct Hybridization microar-
ray (Illumina, San Diego, CA, USA), and 25,559 probes
from the microarray were included for analysis. Probes
for multiple genes were eliminated. The R software run-
ning the lumi and limma packages were used to deter-
mine differentially expressed genes in ligand-treated cells.
Normalized intensity values were log-2 transformed.
To correct for false discovery, we implemented the
Benjamini-Hochberg correction [21]. An additional filter
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for differentially expressed genes was set at 1.5-fold
change in expression in either direction. Array data have
been deposited in the NCBI Gene Expression Omnibus
database [GSE34987].
Data mining
Bioinformatic analyses of enriched gene sets were made
in Pathway Studio (Ariadne Genomics, Rockville, MD,
USA). Fisher’s exact test was applied to determine sig-
nificantly enriched pathways. The gene sets for analysis
of transcription factor (TF) target enrichment, TFT ver-
sion 3.0, were downloaded from the Broad Institute
[22], whereas the gene ontology (GO) categories used
were provided within the software. TFT 3.0 contains sets
of genes that share a common predicted TF binding site as
defined in TRANSFAC version 7.4. The enrichment of
E2F motifs was compared to a random sampling of pro-
moters for all transcription factors in the MSigDb data-
base. The promoter region was defined to be 2kb up- or
downstream of the transcription start site.
Quantitative PCR
For time-course experiments, cells were plated in 6-well
plates and treated with 5 μM GW3965 for 6 to 72 hours
before harvest and RNA isolation. cDNA synthesis was
performed using SuperScript II reverse transcriptase
(Invitrogen). Quantitative PCR (qPCR) was carried out
using Fast SYBR Green Master Mix (Applied Biosys-
tems, Carlsbad, CA, USA) in the 7500 fast real-time
PCR system (Applied Biosystems). Primers (Additional
file 1) for specific genes were designed using Primer3
software. Relative transcript levels were calculated using
the ΔΔct (cycle threshold) method with 36B4 as the
reference gene. Statistical significance was determined
by Student’s t-test.
RNA interference
MCF-7, T-47D, and MDA-MB-231 cells were seeded in
6-well plates (9.6 cm2, area per well) in appropriate
media mentioned above. After 24 hours, cells were
washed with PBS and transfected with either 10 nM
E2F2 siRNA (Dharmacon, Lafayette, CO, USA) or
10 nM non-targeting control (Dharmacon), using Dhar-
maFECT I transfection reagent (Dharmacon). Cells were
counted using the trypan blue staining method and the
Countess automated cell counter (Invitrogen). To vali-
date gene knockdown, RNA isolation, cDNA synthesis
and qPCR were performed in the same way as described
above.
Western blot analysis
After 48 hours of E2F2 siRNA or non-targeting control
treatment, cells were lysed with RIPA lysis buffer. Pro-
tein concentrations were then determined using Qubit®
Protein Assay Kit and fluorometer (Invitrogen, New
York, NY, USA). Total protein (100 μg from each sam-
ple) was loaded onto a 10% polyacrylamide gel. After
electrophoresis, proteins separated by SDS-PAGE were
transferred to a polyvinylidene fluoride (PVDF) mem-
brane (Millipore, Billerica, MA, USA). The membrane
was blocked with 5% nonfat milk in Tris-buffered saline
and Tween 20 (TBST) and then incubated with antibo-
dies against E2F2 (Santa Cruz Biotechnology, Inc., Santa
Cruz, CA, USA) or b-actin (catalog number: A2228,
Sigma, St. Louis, MO, USA) in TBST overnight. The
membrane was then reprobed with appropriate secondary
antibodies conjugated with horseradish peroxidase for
1 hour. Blots were processed using an ECL kit (Thermo
Fisher Scientific, Rockford, IL, USA) and exposed to film.
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) assays were per-
formed as described previously [23,24]. Immunoprecipita-
tions were carried out with E2F2 antibody (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) or corresponding
pre-immune IgG (Santa Cruz Biotechnology). Binding of
E2F2 to response elements was measured by qPCR using
specific primers (Additional file 1).
Clustering of clinical samples and survival analysis
Clinical and microarray gene expression data from a pre-
viously published breast cancer study cohort from
Uppsala, Sweden, were used to determine the correlation
of the expression profiles of the 83 commonly responsive
genes with clinical parameters and disease outcomes [25].
Dendrograms and heat maps were generated using the
Eisen Cluster and Treeview software. Survival data were
analyzed using Kaplan-Meier plot functions (log-rank test)
of the SigmaPlot software. These analyses utilized pre-
viously published and publicly available clinical and
experimental data from patient samples and therefore no
consent or institutional review was required.
Results
Global effects of LXR ligand treatment on gene
expression
Previous studies of LXR ligands and LXRs in cancer cells
have focused on their effects on cell cycle regulation and
cell proliferation [14-17,20]. It is unclear, however, which
LXR-regulated genes are involved in the observed disrup-
tion of cancer cell proliferation. To determine their tran-
scriptomic effects on breast cancer cell gene expression
and to identify potential target mechanisms of LXR
ligands, we performed microarray analysis of gene
expression in MCF-7, T-47D, SK-BR-3, or MDA-MB-231
cells, four well-characterized cell line models of ER+ and
ER- breast cancers, which express both LXRa and LXRb
(Additional file 2) and have previously been shown to be
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sensitive to LXR ligand treatment [20], following either
control treatments with dimethyl sulfoxide (DMSO) vehi-
cle or GW3965 LXR ligand.
Using a false discovery rate-corrected P-value cutoff of
<0.05 and at least a 1.5-fold increase or decrease in
expression, a total of 2,800 genes showed differential
expression in response to ligand treatments in at least
one cell line as compared to vehicle-treated controls.
The results are summarized in Figure 1. ER+ MCF-7
cells exhibited the most robust response with 2,021 dif-
ferentially expressed genes. Only 462 genes were respon-
sive to ligand treatment in ER+ T-47D cells, indicating
significant genomic differences in transcriptional pro-
gramming between cell lines in spite of their common
ER status. Interestingly, ER (ERa) transcript levels
decreased in response to LXR ligand treatment in both
ER+ cell lines. This is consistent with previous observa-
tions of decreased ERa transcript and protein levels in
ligand-treated MCF-7 cells and suggests a potential
mechanism for modulating ER activity and cell prolifera-
tion in ER+ breast cancer cells by LXR ligands [20]. To
further determine the impact of the downregulation of
ER expression on the changes in gene expression following
ligand treatment, we cross-referenced the 193 common
ligand-responsive genes in the two ER+ cells lines and
compared them to a list of 938 estrogen-responsive genes
identified in previously published studies [26-29]. Of the
193 common LXR ligand-reponsive genes in the two ER+
cell lines, 25 are likely downstream targets of ER. In ER-
breast cancer cells, 603 genes were responsive to ligand
treatment in SK-BR-3 cells, and 926 genes were responsive
in the triple-negative MDA-MB-231 cells. Of all the
ligand-responsive genes, 83 (23 upregulated and 60 down-
regulated) were responsive in all four breast cancer cell
lines, including known LXR target genes such as ABCA1
and ABCG1 [30,31], and they represent candidate
mechanisms for the anti-proliferative effects of LXR
ligands in these cell lines.
Ligand treatment downregulates genes involved in cell
growth and proliferation
Out of the 2,800 LXR ligand-responsive genes identified in
our microarray study, 83 showed consistent responses
across all four breast cancer cell lines examined (Addi-
tional file 3). We posited that these conserved responsive
genes are likely involved in core LXR functions, which
may include molecular and cellular processes related to
known metabolic functions of LXRs and their ligands and
also those involved in cell growth and proliferation, which
are the focus of this study. To test this hypothesis, we car-
ried out GO analysis of functional categories that are
enriched in this commonly responsive gene set, using the
Pathway Studio software package.
Since genes involved in the same pathways and pro-
cesses are likely co-regulated, we first divided the set of 83
genes into those that were upregulated (n = 23) following
ligand treatment and those that were downregulated (n =
60). Analysis results revealed that these two groups of
genes are involved in distinctly different biological pro-
cesses (Table 1). The upregulated gene set is significantly
enriched for genes that function in lipid and cholesterol
transport and metabolism, consistent with known func-
tions of LXRs and their ligands. The downregulated gene
set, on the other hand, is overwhelmingly enriched for
genes that are involved in cell cycle regulation, DNA repli-
cation, and other related biological processes associated
with cell proliferation. These findings indicate that ligand-
activated LXRs may block cell proliferation by downregu-
lating genes that are involved in processes critical for
cancer cell division, and the metabolic functions and the
anti-proliferative effects of LXRs are likely regulated via
distinctive transcriptional regulatory mechanisms.
Potential role of E2F2 in anti-proliferative effects of LXR
ligands
The apparently coordinated downregulation of genes
associated with cell growth and proliferation by LXR
ligand treatment suggests the targeting of key TFs by
activated LXRs. To determine whether downregulated
responsive genes shared common cis-regulatory sequence
motifs, we utilized the Pathway Studio software package
to examine their promoter regions (2 kb up- or down-
stream of the transcriptional start sites) for known TF
binding-site motifs. The only sequence motif that showed
significant over-representation in the promoter regions of
this gene set belongs to the E2F family of TFs.
E2F family members are known to regulate the
expression of genes that function in cell cycle regulation
Figure 1 Venn diagram of liver × receptor ligand-responsive
genes across four different breast cancer cell lines. Responsive
genes were defined as those that were statistically significant (false-
discovery rate-corrected P < 0.05) and at least 1.5-fold change in
treated cells compared to vehicle-treated controls. ER+, estrogen
receptor-positive; ER-, estrogen receptor-negative.
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and DNA replication [32,33]. Strikingly, 15 out of the 60
(25%) downregulated genes identified in our microarray
study contain E2F binding-site motifs in their promoter
regions. We performed qPCR analysis of their expres-
sion to confirm their downregulation by LXR ligand
treatment, and found statistically significant (P < 0.05,
Student’s t-test) downregulation in the majority of the
predicted E2F target genes in all cell lines (Figure 2). To
identify the specific E2F family member that might be
regulated by LXR ligands and is involved in mediating
their anti-proliferative effects, we examined the ligand-
responsive microarray data and found E2F2 among the
60 commonly downregulated genes. Time-course analy-
sis of E2F2 transcript levels by qPCR showed decreases
of approximately 30 to 40% compared to vehicle-treated
controls for up to 72 hours following ligand treatment
in MCF-7 cells (Figure 3A). T-47D cells showed the
most robust decrease in E2F2 transcript following
GW3965 treatment, with over 80% decrease after 48
hours. ER- cell line MDA-MB-231 showed a moderate
decrease in E2F2 transcript levels at 48 and 72 hours.
The observed corresponding decreases of E2F2 and
E2F target gene transcript levels suggest a possible
mechanism by which ligand-activated LXRs can block
cell proliferation. To determine the role of E2F2 in breast
cancer cell proliferation, we carried out RNA interference
experiments in MCF-7 and T-47D (ER+) and MDA-MB-
231 (ER-) cells and measured the effects of E2F2 knock-
down, mimicking the effects of LXR ligand treatment, on
cell numbers over a 72-hour period. Transfection of
MCF-7 and T-47D cells with E2F2 targeting siRNAs
resulted in approximately 40 to 60% decrease in E2F2
transcript levels for the ER+ cell lines and 60 to 80%
decrease in the ER- MDA-MB-231 cells (Figure 3B) for
Table 1 Top fifteen over-represented gene ontology (GO) categories of liver × receptor ligand up- and downregulated
genes
GO biological processes P-value
Upregulated
Response to high density lipoprotein stimulus 1.37E-06
Intracellular cholesterol transport 4.57E-06
Cholesterol homeostasis 6.55E-06
Negative regulation of cholesterol storage 6.85E-06
Phospholipid homeostasis 9.59E-06
Positive regulation of cholesterol efflux 1.64E-05
Response to endoplasmic reticulum stress 3.55E-05
Negative regulation of macrophage derived foam cell differentiation 4.14E-05
Phospholipid efflux 4.14E-05
Glutamine metabolic process 7.77E-05
Reverse cholesterol transport 7.77E-05
Positive regulation of protein catabolic process 8.63E-05
Response to nutrient 1.08E-04
Cholesterol efflux 1.47E-04





Nucleotide-excision repair, DNA gap filling 3.52E-13
DNA-dependent DNA replication initiation 2.84E-12
Cell division 1.09E-11
Mitosis 1.41E-08
Response to DNA damage stimulus 2.93E-08
Phosphoinositide-mediated signaling 1.44E-06
DNA unwinding involved in replication 3.23E-06
Modification-dependent protein catabolic process 1.05E-05
Protein K6-linked ubiquitination 1.99E-05
Nucleobase, nucleoside, nucleotide and nucleic acid metabolic process 2.12E-05
DNA strand elongation involved in DNA replication 4.95E-05
Response to organophosphorus 4.95E-05
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the duration of the study compared to the control siRNA
transfected cells. Even though knockdown of E2F2 tran-
scripts was most efficient in MDA-MB-231 cells, protein
levels of E2F2 at 48 hours were not significantly changed
for the ER- cell line (Figure 3C). However, in the two ER
+ cell lines MCF-7 and T-47D, protein levels on E2F2
were significantly decreased after 48 hours. Effects of
E2F2 knockdown on cell counts were significantly differ-
ent from control cells at 72 hours for ER+ cells lines only
(Figure 3D). These findings demonstrate that knockdown
of E2F2 expression was sufficient to disrupt MCF-7 and
T-47D cell proliferation and provide evidence for its role
in the mechanisms of action of LXR ligands in ER+
breast cancer cells.
In contrast, knockdown of E2F2 expression (Figure 3B)
did not affect MDA-MB-231 cell proliferation (Figure 3D),
and this is likely due to the stability of E2F2 proteins in
spite of knockdown of E2F2 transcripts. Correspondingly,
when we examined mRNA levels of E2F target genes in
MCF-7 and MDA-MB-231 cells, 13 out of 15 genes were
downregulated in MCF-7 (Figure 3E), but only 5 out of 15
E2F target genes were downregulated in MDA-MB-231
cells (Figure 3F). Of the E2F family members, only E2F2 is
downregulated in MDA-MB-231 cells following LXR
ligand treatment, whereas in MCF-7 and T-47D, E2F7 is
also downregulated (Additional file 4). Members of
the E2F TF family are known to act in conjunction or in
opposition to each other. In MDA-MB-231, E2F2 is down-
regulated following GW3965 treatment, but E2F5 is upre-
gulated. In the other two ER+ cell lines, E2F2 and E2F7
are both downregulated following treatment. These results
likely reflect the genetic and mechanistic heterogeneity in
these cell lines as well as molecular and clinical differences
between ER+ and ER- breast cancer cells.
To test the possible direct regulation of predicted E2F
target genes by E2F2, we preformed ChIP analysis in
MCF-7 cells and observed strong binding of E2F2 to the
predicted binding site in the promoter region of the
CDC25A gene, and the binding was comparable to
known E2F2 binding sites adjacent to CASP3 and EZH2
(Figure 3G). Moreover, treatment with the LXR agonist
GW3965 significantly reduced E2F2 binding to all three
target gene sites compared to vehicle-treated controls.
No enrichment of binding sites and reduction in binding
were observed in control experiments using pre-immune
immunoglobulin G (IgG) and in exonic regions of target
Figure 2 Expression of predicted E2F target genes responsive to liver × receptor (LXR) ligand treatment was validated by quantitative
polymerase chain reaction (qPCR). (A-D) Expression of fifteen ligand-responsive E2F target genes in control and LXR ligand-treated cells were
validated by qPCR in all four cell lines. Significance was determined by Student’s t-test (P < 0.05), and the error bars represent standard error of
means from three replicate experiments.
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Figure 3 Knockdown of E2F2 decreased cell growth in estrogen receptor-positive MCF-7 and T-47D cells but not estrogen receptor-
negative MDA-MB-231 cells. (A) E2F2 mRNA levels decreased in MCF-7, T-47D and MDA-MB-231 cells following GW3965 treatment. (B) E2F2
mRNA levels decreased following transfection with targeting siRNA. (C) Protein expression of E2F2 following siRNA transfection at 72 hours post-
transfection. (D) Trypan blue staining shows a decrease in MCF-7 and T-47D, but not MDA-MB-231 cell numbers following transfection with
siE2F2 compared to control siRNA. (E) Relative mRNA expression of predicted E2F target genes after E2F2 siRNA transfection in MCF-7 cells. (F)
Relative mRNA expression of predicted E2F target genes after E2F2 siRNA transfection in MDA-MB-231 cells. (G) E2F2 binding to promoter
regions of CDC25A, EZH2, and CASP3 in MCF-7 cells was analyzed by chromatin immunoprecipitation assays. Disruption of E2F2 binding was
observed following 24 hours of liver × receptor ligand treatment (filled bars) compared to vehicle-treated controls (open bars). No enrichment of
binding or disruption following ligand treatment was observed in control immunoprecipitations using pre-immune immunoglobulin or in
negative control regions in the exons of target genes. Significance was determined by Student’s t-test (*P < 0.05, **P < 0.025, ***P < 0.01) and
the error bars represent standard error of means from three replicate experiments.
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genes. These results suggest that downregulation of
E2F2 expression and activity in ER+ breast cancer cells
is a potential mechanism by which cell cycle progression
and cell proliferation are disrupted following treatment
with LXR agonist GW3965 [20].
Expression profiles of the LXR ligand-downregulated
target genes are associated with disease outcome in
breast cancer patients
Microarray analysis of LXR ligand-responsive transcrip-
tomic changes in breast cancer cells uncovered 83 genes
with transcript levels that were altered in all four breast
cancer cell lines selected for this study (Figure 1). Their
conserved responses in cell lines representing diverse
genetic backgrounds and pathologies suggest that LXR
ligands may affect gene networks commonly utilized in
breast cancers. To determine the relevance of these LXR
ligand-responsive genes in breast cancer, we examined
their expression in breast tumors and correlation with
disease outcomes in a previously described cohort of
258 breast cancer patients from Uppsala, Sweden [25].
Because the upregulated (n = 23) and downregulated
(n = 60) ligand-responsive genes appear to have distinct
functions (Table 1), their expression in tumor samples
was analyzed separately.
Hierarchical clustering of patients based on the expres-
sion profiles of the 23 LXR ligand-upregulated genes
grouped them into two major clusters (Figure 4A).
Kaplan-Meier analysis of patient disease-free survival
(DFS), distant metastases-free survival (DMFS), and dis-
ease-specific survival (DSS) showed no differences in dis-
ease outcomes between the two groups (Figure 4B-D).
Clustering of patients with downregulated responsive
genes (Figure 5A), however, resulted in two groups with
statistically significant differences in DFS, DMFS, and
DSS (Figure 5B-D). Specifically, the group of patients
whose tumors expressed lower levels of the downregu-
lated genes, similar to the effects of LXR ligand treat-
ment, had better outcomes compared to the group with
higher expression levels of these genes. Taken together,
these results suggest that LXR ligands target genes that
are involved in key processes in breast cancer biology
and that may play important roles in determining disease
progression, response to therapy, and ultimately, patient
survival.
Discussion
In this study, we performed microarray experiments to
determine changes in gene expression associated with the
anti-proliferative effects of LXR ligands in breast cancer
cells. Our goals were to carry out more comprehensive
characterization of the functions of LXRs and their
ligands in cancer cells, and to identify their mechanisms
of action in order to further evaluate their utility as a
potential target mechanism and therapeutic agent,
respectively, in the treatment of breast cancer. The four
cell lines selected for this study are well-characterized
and represent molecularly and clinically diverse cellular
models of breast cancer, and the proliferation of all four
was blocked by LXR ligand treatment [20]. In addition to
their genotypic differences, including both heritable var-
iations and somatic mutations, these cell lines differ in
their initial tumor histology, ER status, p53 status, HER2/
neu status, responses to targeted therapies and che-
motherapeutic compounds, and their tumorigenic and
metastatic potential. It is not surprising then that they
exhibited vastly different molecular responses to LXR
ligand treatment in terms of the number and identity of
genes that were responsive to the ligand (Figure 1), as
well as the magnitude of change for those genes that
were commonly responsive between cell lines (Additional
file 3). These differences likely reflect genetic and epige-
netic variations between the cell lines, which affect the
chromatin structure, the repertoire and functions of co-
regulatory proteins and TFs, including LXR subtypes and
expression levels, and post-transcriptional regulatory
mechanisms, such as those involving microRNA.
In spite of their significant differences in transcrip-
tional responses, however, the four breast cancer cell
lines in this study do share a core set of 83 LXR ligand-
responsive genes (Figure 1), including those that might
be responsible for the anti-proliferative effects of the
ligand observed in the cell lines [20]. These genes can
be divided into two groups (Table 1) based on their up-
or downregulation by ligand treatment, and each group
appears to carry out distinct LXR functions. The list of
23 upregulated genes includes known LXR target genes
that function in lipid and cholesterol transport and
metabolism, whereas the 60 downregulated genes
include many that function in cell cycle regulation and
DNA replication. This clear delineation of responses
and functions suggests the involvement of discrete
mechanisms that can potentially be exploited in evaluat-
ing existing ligands and in developing novel ligands spe-
cifically for cancer treatment. For example, an ideal LXR
ligand for targeting cancer cells would have minimal
effects on the 23 upregulated responsive genes and their
metabolic functions, thus bypassing the undesired
increases in plasma and liver triglyceride levels seen in
mouse atherosclerosis models following treatments with
some LXR agonists [34,35], and elicit robust responses
in the 60 downregulated responsive genes associated
with cancer cell growth and proliferation.
To further determine the mechanisms of action of
LXR ligands on cancer cell proliferation, we analyzed
the cis-regulatory sequences of the 83 universal LXR
ligand-responsive genes identified in our microarray
study for the presence of TF binding-site motifs, which
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may provide clues to factors that may be involved in the
observed changes in gene expression. Only the E2F
binding-site sequence motif is significantly enriched and
only in the promoter regions of the set of 60 downregu-
lated responsive genes. Correspondingly, one of the most
downregulated responsive genes was E2F2 (approxi-
mately 2.5- to 8.0-fold decrease following ligand treat-
ment). Knockdown of E2F2 expression by RNA
interference disrupted ER+ breast cancer cell prolifera-
tion (Figure 3D), indicating that downregulation of E2F2
expression by ligand activation of LXRs is a potential
mechanism of action for LXR ligands and their anti-pro-
liferative effects in ER+ breast cancer cells. E2F2 RNA
interference showed significant decrease of some of the
predicted E2F target genes in both ER+ (Figure 3E) and
ER- cell lines (Figure 3F). Further ChIP anaylsis showed
that indeed in ER+ MCF-7 cells, E2F2 binds to the
response element of CDC25A (Figure 3G), and this bind-
ing is disrupted following treatment with the LXR ligand
GW3965. CDC25A is a cell-division cycle gene whose
phosphatase action is required for cell progression from
the G1 phase of the cell cycle to the S phase. It has
previously been shown that decreases in proliferation of
both MCF-7 and Vcr-R, another human breast cancer
cell line, after treatment of natural tetrasulfides, are due
to inhibition of CDC25 [36]. Furthermore, overexpres-
sion of CDC25A in small breast carcinomas is associated
with poor survival in patients [37].
It is not clear, however, whether E2F2 is directly tar-
geted by LXRs or through an indirect mechanism. When
we examined the genomic regions proximal to the E2F2
gene for LXR response-element sequence motifs, we did
not detect any candidate LXR binding-site. This can be
due to the sensitivity of the position weight matrix model
we used, or the response element for E2F2 regulation
might be located in a distal enhancer region not included
in our analysis. Activated LXRs may also indirectly regu-
late E2F2 expression by tethering to another TF or by
regulating the expression of another factor, which in turn
affects the expression of E2F2. Alternatively, the expres-
sion of E2F2 and the other downregulated responsive
genes may merely reflect the disruption of cell cycle pro-
gression and the observed accumulation of G1/G0 cells
compared to the cycling vehicle-treated control cells as
Figure 4 Expression profiles of commonly upregulated liver × receptor ligand-responsive genes clustered breast cancer patients into
two groups with similar disease outcomes. (A) Hierarchical clustering of 258 breast cancer patients by their expression profiles of 23 commonly
upregulated genes defined two major patient groups. Kaplan-Meier analysis was carried out on two groups of patients defined by hierarchical
clustering for (B) disease-free survival (DFS), (C) distant-metastasis-free survival (DMFS), and (D) disease-specific survival (DSS). Statistical significance
of the differences between the two survival plots was determined by the log-rank test and indicated by the resulting P-value.
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seen in a previous study. This, however, is unlikely
because the changes in gene expression assayed in this
study were carried out 48 hours after ligand treatment,
whereas the differences in cell cycle progression were
observed at 72 hours [20]. The effects of LXR ligands on
cancer cells may also involve non-genomic mechanisms,
which can regulate cell proliferation and gene expression
via post-translational modifications and signal transduc-
tion pathways. These hypotheses regarding the mechan-
isms of action of LXR ligands in cancer cells and the role
of E2F2 and other E2F family members in mediating
their anti-proliferative effects await further testing and
investigation.
The ultimate goals of this study are to understand and
exploit the potential impact of LXR ligands on breast
cancer progression and patient survival. This study has
defined a set of genes whose expression levels were
altered in response to LXR ligand treatment in four cell
line models of breast cancer. Expression profiles of
these genes in breast tumors from a clinically diverse
cohort of 258 breast cancer patients were examined to
assess their in vivo relevance [25]. Hierarchical cluster-
ing of patients with the expression profiles of the 60
downregulated responsive genes separated them into
two groups with statistically significant differences in
disease outcomes (Figure 5). Patients whose tumors
Figure 5 Expression profiles of commonly downregulated liver × receptor ligand-responsive genes clustered breast cancer patients into
two groups with good and poor disease outcomes. (A) Hierarchical clustering of 258 breast cancer patients by their expression profiles of 60
commonly downregulated genes defined two major patient groups. Kaplan-Meier analysis was carried out on two groups of patients defined by
hierarchical clustering for (B) disease-free survival (DFS), (C) distant-metastasis-free survival (DMFS), and (D) disease-specific survival (DSS). Statistical
significance of the differences between the two survival plots was determined by the log-rank test and indicated by the resulting P-value.
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expressed lower levels of these 60 genes experienced
longer survival times than patients in the higher expres-
sion cluster. In addition to disease outcomes, patients in
these groups also differed in important clinical para-
meters, such as ER status, PR status, lymph node status,
and tumor grade (Table 2), consistent with the known
association of these parameters with disease outcomes.
This strong association of the 60-gene signature with
patient survival and clinical parameters indicates that
LXR ligand treatment elicited transcriptional responses
in breast cancer cells similar to expression profiles
observed in tumors from patients with significantly bet-
ter outcomes. Whether LXR ligand treatment of patients
will alter the transcriptional programming in tumors
and, ultimately, tumor growth and disease outcome,
remain to be determined clinically.
Conclusions
LXR ligands target gene networks critical for cell growth
and proliferation and disease progression, including
those regulated by E2F transcription factors, and war-
rant further study and consideration as potential agents
in the prevention and treatment of breast cancers.
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